Samsung Bioepis has declared its strategic research collaboration with G2GBIO to develop long-acting semaglutide and other new therapies. The partnership also includes Epis NexLab, the sister company of Samsung Epis Holdings. As a result of this partnership, Samsung Bioepis will obtain an exclusive license to develop and commercialize two new and innovative drug assets. Notably, the program focuses on long-acting semaglutide created with G2GBIO’s proprietary microsphere technology.
At the same time, Epis NexLab will collaborate on the development of a long-acting microsphere drug delivery platform. The initiative aims to enhance sustained-release drug formulations. Consequently, the companies expect better therapeutic results and more effective treatment methods. Under this agreement, Samsung Bioepis is granted full licensing rights for this long-acting semaglutide asset. In addition, Samsung Bioepis is granted an option to license another asset developed by G2GBIO. Furthermore, Samsung Bioepis gains first negotiation rights for three additional novel drug candidates. These assets will be determined in future discussions between the companies.
Meanwhile, Epis NexLab will support the co-development of the microsphere-based delivery platform. The company will leverage G2GBIO’s proprietary technology to advance innovative drug delivery solutions. However, the financial terms of the agreement remain confidential.
“This agreement represents an important step in expanding our drug delivery capabilities and pipeline,” said Kyung-Ah Kim, President and Chief Executive Officer, at Samsung Bioepis. “By leveraging G2GBIO’s proprietary microsphere technology and collaborating with Epis NexLab, we look forward to the development of innovative therapies and deliver meaningful treatment options to patients.”
Collaboration to Accelerate Advanced Drug Delivery
The collaboration highlights the growing industry focus on long-acting biologics and sustained-release formulations. These technologies help in reducing the frequency of dosing and increasing patient compliance. Moreover, microsphere drug delivery systems help in the controlled release of medication for longer periods. As a result, pharmaceutical companies are increasingly opting for this method in the treatment of metabolic diseases. Thus, with this association, Samsung Bioepis has enhanced its strategy in biopharmaceutical innovation. At the same time, the collaboration expands its pipeline of advanced therapeutics.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
